Mario Tama/Getty Images News An ETF focused on the rapidly growing sector of GLP-1 receptor agonists and other weight management drugs made its trading debut on Tuesday. The Roundhill GLP-1 & Weight Loss ETF ( NASDAQ: OZEM ) started trading on Nasdaq , Roundhill Investments said. The new ETF seeks to offer exposure to the exponential growth forecast for the sector.
The obesity treatment market is projected to grow by more than 16x its current size to $100B by 2030, according to Goldman Sachs Research. "With obesity rates nearly tripling since 1975 and projected to affect over half the population by 2035, the market for weight loss drugs is in its early stages, offering substantial growth potential for companies pioneering innovation in the space," said Dave Mazza, CEO of Roundhill Investments. OZEM's top four holdings are Eli Lilly ( LLY ), Novo Nordisk ( NVO ), Innovent Biologics ( OTCPK:IVBIY ) ( OTCPK:IVBXF ), and Zealand Pharma ( OTCPK:ZLDPF ).
More on Weight Loss Drugs Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead Genetics may determine who responds well to Wegovy: report One in eight U.S. adults admits to GLP-1 usage as public awareness climbs Microcap Mangoceuticals doubles on plan to sell cheap oral GLP-1 weight loss meds.